TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace
BETHESDA, Md., May 20, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, announced its common stock is trading on the OTC Markets' OTCQB marketplace under the ticker symbol "TNIB" commencing May 17, 2013. Investors will be able to view the real-time Level II stock quotes for TNIB at http://www.otcmarkets.com/stock/TNIB/quote.
Noreen Griffin, CEO of TNI BioTech, Inc. stated, "We are very pleased to provide this additional trading venue to further enhance liquidity, particularly for our current and future shareholders."
The transition to the OTCQB does not change TNI BioTech's reporting obligations with the Securities and Exchange Commission (SEC) under applicable federal securities laws. The company intends to continue to file its quarterly reports on Form 10-Q, annual report on Form 10-K and current reports on Form 8-K. The company anticipates the timely reporting of its second fiscal quarter ending June 30, 2013 on or before August 14, 2013.
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company with the goal of benefitting patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system, using our patented immunotherapy.
Our products, technologies and patents are designed to harness the power of the immune system to improve the treatment of cancer, chronic infections such as HIV/AIDS, and autoimmune diseases and, such as Crohn's disease, other types of inflammatory bowel disease, and multiple sclerosis.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells, leading to an activation and expansion of various cells of the immune system.
Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by augmenting the number and functions of both T cells and natural killer (NK) cells in patients with deficient immune responses associated with advanced cancer or HIV/AIDS, and by rebalancing the immune responses in patients with autoimmune diseases, including Crohn's disease and multiple sclerosis.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
SOURCE TNI BioTech, Inc.
More by this Source
The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
Mar 07, 2014, 10:00 ET
TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
Mar 06, 2014, 10:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.